Decisions under uncertainty are prevalent, but come under two distinct types. Risk, which has unknown outcomes but known probabilities for those outcomes and ambiguity which contains both unknown outcomes and unknown probabilities. Although there have been several studies linking affect and aversion to ambiguity, there have been no studies that have to identify how changing one's affective response can change their choices. A total of 166 adults ( = 36.54, = 11.80) participated in an online study through Prolific. Participants were presented with a lottery on each trial which varied on its uncertainty type (risky vs ambiguous) and winning characteristics (winning probability and amount). Half of the ambiguous lotteries were paired with an neutral image (e.g., office supplies), while the other half was paired with an emotionally evocative image (e.g., burning house) that was hypothesized to incidentally influence their decisions. As measured by both raw choice data as well as through a computational model, participants were more averse to ambiguity when the lottery was paired with an emotionally evocative image. Follow-up analyses revealed that only lotteries in which the computational model predicted the participant would choose the lottery were affected by the images. This study highlights the phenomenon in which one's awareness of an affective stimulus can alter its impact on their decisions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10862981PMC
http://dx.doi.org/10.21203/rs.3.rs-3873970/v1DOI Listing

Publication Analysis

Top Keywords

unknown outcomes
8
paired emotionally
8
emotionally evocative
8
evocative image
8
computational model
8
synchronized incidental
4
incidental affect
4
affect changes
4
ambiguity
4
changes ambiguity
4

Similar Publications

Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies.

JAMA Neurol

January 2025

Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, Beijing, China.

Importance: Autoantibodies targeting astrocytes, such as those against glial fibrillary acidic protein (GFAP) or aquaporin protein 4, are crucial diagnostic markers for autoimmune astrocytopathy among central nervous system (CNS) autoimmune disorders. However, diagnosis remains challenging for patients lacking specific autoantibodies.

Objective: To characterize a syndrome of unknown meningoencephalomyelitis associated with an astrocytic autoantibody.

View Article and Find Full Text PDF

Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors.

JAMA Intern Med

January 2025

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Importance: Evidence on cardiovascular benefits and safety of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is mainly from placebo-controlled trials. Therefore, the comparative effectiveness and safety of individual SGLT-2 inhibitors remain unknown.

Objective: To compare the use of canagliflozin or dapagliflozin with empagliflozin for a composite outcome (myocardial infarction [MI] or stroke), heart failure hospitalization, MI, stroke, all-cause death, and safety outcomes, including diabetic ketoacidosis (DKA), lower-limb amputation, bone fracture, severe urinary tract infection (UTI), and genital infection and whether effects differed by dosage or cardiovascular disease (CVD) history.

View Article and Find Full Text PDF

Importance: Trials have not demonstrated superiority of alteplase or tenecteplase vs standard care in patients with mild stroke and have raised safety concerns. Prourokinase is an alternative fibrinolytic that may have a favorable safety profile, and the benefit-risk profile of prourokinase in mild stroke is unknown.

Objective: To investigate the efficacy and safety of prourokinase in mild ischemic stroke within 4.

View Article and Find Full Text PDF

Importance: No large randomized clinical trial has directly compared empagliflozin with dapagliflozin, leaving their comparative effectiveness regarding kidney outcomes unknown.

Objective: To compare kidney outcomes between initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who were receiving antihyperglycemic treatment.

Design, Setting, And Participants: This target trial emulation used nationwide, population-based routinely collected Danish health care data to compare initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who received antihyperglycemic treatment between June 1, 2014, and October 31, 2020.

View Article and Find Full Text PDF

Background: The role of activating alterations in the MAPK pathway in predicting immunotherapy efficacy in lung squamous cell carcinoma (LSCC) patients is largely unknown. The aims of the randomized, phase II SQUINT trial were to assess the efficacy of nivolumab plus ipilimumab (NI) versus platinum-based chemotherapy plus nivolumab (N-CT) and to identify clinically available biomarkers of response to immunotherapy in patients with advanced or metastatic LSCC.

Methods: SQUINT was an open-label, randomized, parallel, non-comparative, phase II trial of NI versus N-CT in chemo-naïve, metastatic or recurrent LSCC adult patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!